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Introduction
Diabetes mellitus is a lifelong disease affecting an increasing number of people worldwide (International Diabetes Federation, n.d.) . Diabetes is generally divided into type 1 and type 2 diabetes mellitus: the former is characterized by beta cell destruction, the latter by insulin resistance and impaired beta cell function. The common denominator is high blood glucose (DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study; Stratton, Kohner, Aldington, & Turner, 2001) . Late complications of diabetes include macrovascular and microvascular disease. Diabetic microvascular complications in the eye -retinopathyoccur in both type 1 and type 2 diabetes, and they affect the blood vessels of the retina (DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study; Lutty, 2013; Stratton et al., 2001 ; UK Prospective Diabetes Study (UKPDS), 1991). Diabetic microvascular disease of the macula may induce macular edema, which can severely reduce visual acuity. The prevalence of diabetic macular edema (DME) ranges from 2.1% to 7.5% in different patient populations (Heintz, 2012; Hirai, Knudtson, Klein, & Klein, 2008; Raymond et al., 2009; Varma et al., 2014) ; diabetic retinopathy is a major cause of severely impaired vision and blindness globally (Bourne et al., 2014) . Among DME patients, visual impairment is regarded as the most feared late diabetic complication (Janzen Claude, Hadjistavropoulos, & Friesen, 2014) . In recent years, patient-reported outcome measures have acquired greater importance in capturing patients' thoughts and feelings. Among the dimensions included in patient-reported outcome measures are quality of life, health-related quality of life, and visual function (Denniston, Kyte, Calvert, & Burr, 2014; Leksell, Wikblad, & Sandberg, 2005; Weldring & Smith, 2013; Wikblad, Smide, & Leksell, 2014) .
As defined in the Early Treatment Diabetic Retinopathy Study (ETDRS), (Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report number 1. Early Treatment Diabetic Retinopathy Study research group, 1985) clinically significant DME is sight threatening and requires treatment. Fig. 1 shows a fundus and optical coherence tomography (OCT) with moderate DME compared with a healthy fundus and macular OCT. Laser therapy was established in 1985 and has been shown to reduce the risk of severe vision loss by 50% (Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report number 1. Early Treatment Diabetic Retinopathy Study research group, 1985). However, improvement in visual acuity by laser treatment is limited (Beck et al., 2009 ). In 2010, it was first reported that repeated intravitreal administration of ranibizumab, an inhibitor of vascular endothelial growth factor (VEGF), reduces macular edema and improves visual acuity in patients with visual impairment as a result of DME (Massin et al., 2010) . Other studies using ranibizumab (Elman, Elman, Aiello, Beck, & Bressler, 2010; Mitchell et al., 2011; Nguyen et al., 2012) and another inhibitor of VEGF, aflibercept (Do, Nguyen, Boyer, & Schmidt-Erfurth, 2012) , have reported similar findings. A strong association between visual acuity and patient-reported visual function independent of the severity of retinopathy and other complications has been found in diabetic patients (Gonder et al., 2014; Hirai, Tielsch, Klein, & Klein, 2011; Klein, Moss, Klein, Gutierrez, & Mangione, 2001; Trento et al., 2013; Tsilimbaris, Kontadakis, Tsika, Papageorgiou, & Charoniti, 2013) . The improvement in visual acuity induced by anti-VEGF treatment for DME observed in pivotal clinical trials has been found to be associated with enhanced visual function measured with the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Korobelnik et al., 2014; Mitchell, Bressler, Tolley, et al., 2013) , especially if the better-seeing eye has been treated Mitchell et al., 2013) .
In Sweden, intravitreal administration of anti-VEGF drugs for sight-threatening DME is now part of routine clinical care. Previously, health-related quality of life and visual function were investigated in Swedish diabetic patients participating in a screening program for diabetic retinopathy (Heintz, Wirehn, Peebo, Rosenqvist, & Levin, 2012) . However, information is limited about patient-reported health-related quality of life and visual function in patients with DME about to undergo intravitreal anti-VEGF treatment for visual impairment.
Aims of this cross-sectional study
• To describe visual function (NEI VFQ-25) and patient-reported health-related quality of life (36-item short-form health survey ) in a cohort of Swedish diabetic patients about to undergo anti-VEGF treatment for visual impairment due to DME in routine clinical care.
• To explore the relationship between patient-reported visual function and health-related quality of life with regard to visual impairment, degree of retinopathy, and whether treatment was planned for the better-or worse-seeing eye.
• To analyze the correlation between the two different objective measurements of visual acuity.
Methods

Subjects
This study enrolled participants with diabetes of either sex aged 18 years or older who were about to receive treatment with ranibizumab (Lucentis) for visual impairment due to DME. The patients had to be Swedish speaking and have the cognitive ability to complete the surveys and participate in an interview. Enrollment took place from May 2012 to February 2014 at two county hospitals in Sweden. We excluded patients who had previously been treated with intravitreal anti-VEGF for DME. All patients who met the inclusion criteria were asked about study participation.
Ethical considerations
This study was approved by the Regional Ethical Review Board in Uppsala, Sweden, and was conducted in accordance with the tenets of the Declaration of Helsinki. The participants obtained written and verbal information related to the study. All the participants gave their written informed consent. The data were labeled using code numbers and were handled with respect for the participants' privacy and integrity.
Clinical assessment
Social background characteristics, including age, weight, sex, level of education, marital status, and information about employment or retirement status, were collected from all patients by interview. Data about the duration of diabetes, diabetes treatment, and late diabetic complications were obtained from medical records. Late complications included retinopathy, nephropathy, neuropathy, and macrovascular disease (previous stroke, transitory ischemic attack, or myocardial infarction). Blood pressure was measured, and glycosylated hemoglobin (Lilja et al., 2013) level was obtained from electronic patient records. The patients also specified their number of late diabetic complications.
The initial eye examination included measurement of best-corrected visual acuity with the ETDRS or Snellen chart, slit-lamp examination of the anterior segment, intraocular pressure measurement, fundus biomicroscopy, and measurement of retinal thickness by OCT (Topcon Corporation, Tokyo, Japan).
We performed grading of diabetic retinopathy with indirect ophthalmoscopy as follows: mild non-proliferative diabetic retinopathy (NPDR); moderate NPDR; severe NPDR; or proliferative diabetic retinopathy (Wilkinson et al., 2003) . Clinically, significant diabetic macular edema was defined according to ETDRS (Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report number 1. Early Treatment Diabetic Retinopathy Study research group, 1985). Based on the patient's better-seeing eye, visual impairment was categorized into three groups: normal vision logarithm of minimum angle of resolution (logMAR) ≤0.10; mild visual impairment logMAR 0.20-0.50; and moderate/severe visual impairment logMAR ≥0.60. The degree of diabetes retinopathy was categorized based on the worse-seeing eye as mild/ moderate, severe, or proliferative.
All the patients received two questionnaires -NEI VFQ-25 and SF-36 -at baseline. The patients could choose either to answer the questionnaires at the clinic or to take them home, answer them there, and return the completed forms by mail to the clinic.
Questionnaires
The eye-specific questionnaire, NEI VFQ-25, reflects the respondent's self-reported visual function in subscales: general health; general vision; ocular pain; near activities; distance activities; driving; color vision; peripheral vision and social functioning; role difficulties; and dependency Mangione et al., 1998) . The instrument has been validated for Swedish-speaking patients in the EMGT-study (Eriksson, Sjöstrand, & Kroksmark, 2008) . We employed the manual for scoring (Mangione, 2000) . The subscale scores were 0-100, where a higher NEI VFQ-25 score indicates better visual functioning.
The SF-36 (Maruish) measures eight dimensions of health-related quality of life: physical function; role functioning (physical limitations); bodily pain; general health; vitality; social function; role functioning (emotional limitations); and mental health. The SF-36 has been validated and translated into Swedish (Sullivan, Karlsson, & Ware, 1995) . This survey was designed for self-administration (Ware & Sherbourne, 1992) .
Methods for measuring visual acuity
We measured visual acuity either according to the ETDRS using the ETDRS letter chart at a distance of 2 m or using the Snellen chart at 5 m. ETDRS visual acuity (number of letters) was measured with the eyes planned for anti-VEGF treatment. We measured visual acuity for the other eyes using the Snellen chart. Snellen values were converted to logMAR with the formula logMAR = -log (decimal acuity) (Holladay, 1997) .
Data analysis
SPSS (version 22, SPSS Inc., Chicago, IL, USA) was used for statistical analyses. We followed the manual for NEI VFQ-25 in calculating the scale conversions and subscale scores with 11 vision-related constructs plus an additional single-item general health question. The driving subscale had a high rate of missing data (17/59, 29%), and we calculated the results for 42 patients, according to the manual (Mangione, 2000) . A p value b0.05 was considered statistically significant. After verifying that they were equivalent, we merged the patients from the two eye clinics into a single cohort.
Mean scores, standard deviation (SD), and range were calculated for the subscales in SF-36 and NEI VFQ-25. We used analysis of variance (ANOVA) to examine the relationship between NEI VFQ 25 and SF-36 with regard to visual impairment, degree of retinopathy, and whether treatment was planned for the better-or worse-seeing eye. We employed the Spearman correlation analysis to analyze the correlation between ETDRS and logMAR values. Tukey's post hoc test was used to determine subgroup differences.
Results
Study subjects
We enrolled 63 patients in this study. Two patients declined participation, and four patients discontinued participation after inclusion. In all, 59 patients completed the study.
Patient demographics and characteristics
Sociodemographics and clinical characteristics of the included participants appear in Table 1 . The study sample was equally distributed regarding sex. The mean age was 68.5 (±10.0) years. Over half the participants had completed elementary school, and eight had attained university-level education. Most of the participants (64%) were cohabiting. The majority of participants (66%) had retired. Of the patients, 54 (92%) had type 2 diabetes. Regarding late diabetic complications, including DME, 40 (68%) patients had two or more late complications (Table 1) . Over 50% of the patients had mild or moderate diabetic retinopathy. In 61% of the patients, treatment was planned for the worse-seeing eye (WSE) ( Table 2 ). The mean ETDRS score in the eye planned for treatment was 63.9 ± 13.2; it was 73.3 ± 12.8 in the eye for which no treatment was planned. Almost 30% of the patients had previously undergone treatment with panretinal laser photocoagulation in the eye planned for DME treatment. Over 60% of patients had previously received laser treatment for DME in the eye planned for treatment (Table 3) .
Visual function (NEI VFQ-25) in the cohort with DME
With NEI VFQ-25, the subjects showed the lowest score for the subscale of general health (mean 35.65 ± 22.04) and the highest for dependency (mean 93.48 ± 18.12) ( Table 4) .
3.4. Self-reported health-related quality of life (SF-36) in the cohort with DME For SF-36, the subjects gave the lowest score in the subscale of general health (mean 56.55 ± 22.14) and the highest for the subscale of role emotional (mean 88.73 ± 22.32) ( Table 4) . 
. Degree of visual impairment
With the NEI VFQ-25, significant relationships were found between the degree of visual impairment and number of subscales (Table 5 ). Tukey's post hoc tests demonstrated a significant difference between the participants with normal vision compared with participants that were moderate or severe in eight of the subscales.
For SF-36, ANOVA showed no significant differences in degree of visual impairment, level of retinopathy, or which eye was planned for treatment in any of the SF-36 domains (data not shown).
Planned treatment
Regarding which eye was planned for treatment, we found a significant relationship for NEI VFQ-25 and the subscales of general vision, social functioning, role difficulties, and driving. Table 5 indicates that the participants for whom treatment was planned for the better-seeing eye (BSE) rated significantly lower than participants in whom treatment was planned for the WSE (post-hoc Tukey).
Level of retinopathy
The level of retinopathy showed no significant relation to any of the NEI VFQ-25 subscales (data not shown).
Analysis of correlation between two objective measurements of visual acuity
The Spearman correlation between ETDRS and Snellen logMAR values showed a significant negative correlation (r = −0.98, p = 0.000).
Discussion
This study found that diabetic patients with visual impairment as a result of DME about to undergo anti-VEGF treatment had a very low score for the VFQ-25 subscale of general health. Although the majority of the patients also have undergone laser treatment, they scored low general health as pointed out in a previous study (Turkoglu et al., 2015) .
In most of the VFQ-25 subscales, patients with moderate or severe visual impairment had lower scores than patients with normal vision. Furthermore, our results indicate that patients for whom treatment was planned for the BSE scored lower on general vision, social function, and role difficulties than patients for whom treatment was planned for the WSE. By contrast, no differences were found when the cohort was divided into subgroups according to level of retinopathy. This means that patients with visual impairment due to DME have reduced general health, but the diagnosis of DME or diabetes retinopathy in itself has no or a limited effect on general health. Regarding health-related quality of life measured using the SF-36, we found no differences when the sample was divided into subgroups according to degree of visual impairment, level of retinopathy, or treated eye. This indicates that the SF-36 may not be capable of capturing all relevant vision-related aspects of health-related quality of life.
In this study, we recruited patients from routine clinical care at two medium-sized county hospitals. Overall, the patient demographics, clinical characteristics, and visual functioning in the present clinical study were comparable with baseline characteristics in large pivotal clinical trials with ranibizumab for DME Mitchell et al., 2011) . In the present study, we found a wide range in several baseline variables, such as age, glycosylated hemoglobin, weight, and blood pressure, which suggests heterogeneity among the included patients. Our findings appear to indicate that the diabetic population with DME in need of anti-VEGF treatment in the real-world setting is less homogeneous with regard to background characteristics than patients recruited in a clinical trial. The patient sample in the present study was relatively small. However, this study provides valuable information about patients offered treatment for DME in clinical settings.
The most unexpected result in this study was the low scoring on the NEI VFQ-25 subscale for general health-both from a clinical viewpoint and when compared with other similar studies (Trento et al., 2013; Turkoglu et al., 2015) as well as in those on patients with glaucoma (Kong, Zhu, Hong, & Sun, 2014) and patients diagnosed before the age of 30 years (Hirai et al., 2011) . One possible explanation is that the majority of patients in our sample had at least one other diabetes-related complication in addition to DME. It is well known that two or more diabetes-related late complications have an impact on general health (Heintz, 2012; Leksell et al., 2005; Rubin & Peyrot, 1999; Wikblad et al., 2014) . In particular, neuropathy in combination with retinopathy may lead to a substantial negative impact on general health. In the present study, respondents reported that they had sensory loss, which is suggestive of neuropathy in the hands or feet. However, one weakness with this study is the lack of a control group, which does not allow a direct comparison with a comparable patient cohort or sample.
VFQ-25 analysis showed that there was a relationship with visual impairment in most of the subscales. It seems reasonable to suppose that visual impairment affected those subscales. This is confirmation of the fact that from the patient's perspective, vision has a huge impact on daily life. Furthermore, the particular eye treated played an especially significant role for general vision, social functioning, role difficulties, and driving. For the majority of patients in our sample, treatment was planned for the BSE with visual impairment. The third subgroup analysis on level of retinopathy found no differences among any of the subscales in the NEI VFQ-25. This indicates that the diagnosis of diabetes retinopathy in itself has no or a limited effect on a patient's reported outcome in terms of visual functioning. Heintz et al. (2012) arrived at similar results in their thesis. For that reason, it is important that patients regularly undergo fundus photography because even severe retinopathy can occur without symptoms.
Our analysis of the two different objective methods for measuring visual acuity -the ETDRS and Snellen charts -showed a strong correlation. Measurement of visual acuity according to the ETDRS gives an accurate value, especially if visual acuity is reduced (Falkenstein et al., 2008) , but it is more time consuming than standard acuity testing using the Snellen chart. In real-world settings, as was the case in the present study, the ETDRS chart is generally preferable for diagnosis and follow-up of the eyes subject to anti-VEGF treatment.
In conclusion, this study found that patients with diabetes who were going to undergo anti-VEGF treatment for visual impairment due to DME gave a low rating for their general health as measured with the visual function-specific NEI VFQ-25. It is important to increase the awareness of this finding among healthcare professionals dealing with this group of patients. This study has relatively small sample size due to the number of patients that received the treatment. But the value of the study is that it is implemented in real-world settings, and the results of the study can therefore be generalized for the group of Swedish patients with diabetes about to undergo anti-VEGF treatment for sight-threatening DME.
More research is needed to examine the underlying reasons for this low score in general health. It is crucial to increase our understanding of the underlying mechanisms so as to promote improvements in the treatment of this group of patients. Further, it is now important to follow patient cohorts or samples while on treatment to monitor potential changes in SF-36 and VFQ-25 scores induced by anti-VEGF treatment for DME. 
